



# Neuroendoscopic Intervention in Posthemorrhagic Hydrocephalus : Feasibility and Outcomes

Yura Kim<sup>1</sup>, Joo Hi Kim<sup>1</sup>, Jeong Eun Shin<sup>1</sup>, Hoseon Eun<sup>1</sup>, Junggho Han<sup>1</sup>, Min Soo Park<sup>1</sup>, Seung Hwan Baek<sup>1</sup>, Sumin Lee<sup>1</sup>, Sungbo Shim<sup>1</sup>, Yoonmi Jeong<sup>1</sup>, Ching-yu Lin<sup>1</sup>, Eun-Kyung Park<sup>2</sup>, Kyu-Won Shim<sup>2</sup>, Dong-Seok Kim<sup>2</sup>

Divison of Neonatology , Yonsei University Severance Children's Hospital<sup>1</sup>,  
Department of Pediatric Neurosurgery , Yonsei University Severance Children's Hospital<sup>2</sup>

## Abstract

### Background:

To evaluate the feasibility of active neuroendoscopic lavage (NEL) for posthemorrhagic hydrocephalus (PHH) in preterm infants and to assess associated clinical outcomes.

### Methods:

Medical records of infants with PHH treated at Severance Children's Hospital between 1998 and 2023 were retrospectively reviewed. Patients were classified into two groups: active NEL (Group A) and conservative care (Group B). The presence of fibrinolysis therapy within Group A was also examined. Baseline demographics, surgical characteristics and shunt-related outcomes were compared.

### Results:


Patients in Group A underwent VP-shunt placement at a later postnatal age and later postmenstrual age, compared to Group B. The duration of first EVD to VP-shunt was longer in group A than group B. In Group A, the fibrinolysis (+) subgroup underwent initial surgery earlier but received VP shunt placement at a comparable PMA to the non-fibrinolysis group. The VP-shunt-related complications were lower in group A than group B, while fibrinolysis therapy showed no significant difference.


### Conclusion:


Active and early neuroendoscopic intervention improved PHH control and reduced infection rates, allowing delayed but safer shunt insertion with better growth. Larger, severity-matched cohorts and integrated brain MRI analysis are needed to further elucidate the long-term neurodevelopmental impact of early intervention.

## Introduction

- Posthemorrhagic hydrocephalus (PHH) is a critical complication of high grade intraventricular hemorrhage (IVH) in preterm infants.
- Recently, the neuroendoscopic intervention (lavage) has been introduced as another promising treatment option.
- Neuroendoscopic intervention (lavage) (NEL)**







- Minimal invasive surgery & direct removal of blood product in ventricle
  - ↓ burden of inflammation, ↑ CSF circulation, ↓ needs for shunt revision
- lower mortality & infection rates compared to conventional surgical methods.
- We aimed to evaluate the feasibility of active neuroendoscopic intervention as part of the treatment strategy for PHH.

## Methods

- Retrospective cohort study
- Study population
  - Preterm infants born in January 1998 – December 2023
  - Admitted in Severance Hospital NICU (Both Inborn & transferred patients)
  - Diagnosed with postnatal IVH with PHH
  - Underwent surgical intervention
- Comparison between groups:**
  - Active neuroendoscopic intervention (Group A) and conservative care (Group B)
  - Presence of fibrinolysis therapy within Group A
  - Following variables were compared:
    - Gestational age, birth weight, sex
    - Postnatal days at diagnosis of IVH, first operation and VP shunt
    - PMA at VP shunt
    - Frequency of operation, interval between first operation and VP shunt
    - VP shunt rate
- Active neuroendoscopic intervention (Group A)**
  - 2008 – 2023
  - Temporary treatment:
    - Bedside EVD insertion
    - Active neuroendoscopic lavage, 3-weeks interval
    - ± fibrinolytic therapy via EVD catheter (urokinase or tPA)
  - Permanent treatment: VP shunt
- Conservative care (Group B)**
  - 1998 - early 2008
  - Temporary treatment : Ventricular tapping or EVD
  - Permanent treatment: V-P shunt
- Primary outcome:** VP shunt- related complication rate
  - Shunt –related infection within 1 year
  - Shunt – revision within 1 year
- Statistical analysis**
  - SPSS Statistics for Windows, version 23.0 (SPSS Inc., Chicago, IL., USA)
  - Continuous variables: Median and Interquartile range (IQR)
  - Analysis
    - Mann-Whitney U for continuous variables
    - Chi-square test or Fisher's exact test for categorical variables
  - Statistical significance: P < 0.05


## Results

### Baseline and Surgical Characteristics Between Group A & B

| Values                                   | Group A (N=109)  | Group B (N=20)   | P      |
|--|------------------|------------------|--------|
| Gestational age, week                    | 27.4 [26.3–29.3] | 29.2 [27.1–31.5] | 0.018  |
| Weight at birth, g                       | 1037 [820–1397]  | 1275 [1012–1700] | 0.056  |
| Male, n (%)                              | 60 (55)          | 10 (50)          | 0.808  |
| Inborn, n(%)                             | 16 (14.7)        | 17 (85)          | <0.001 |
| Postnatal days at diagnosis of IVH≥ GIII | 7 [2-14]         | 9.5 [6.3-17.8]   | 0.046  |
| Postnatal days at first operation        | 60 [30–89]       | 63 [30–88]       | 0.431  |
| Frequency of operation                   | 4 [2–5]          | 2 [1–3]          | <0.001 |
| Postnatal days at VP shunt, days         | 141 [109–171]    | 93 [70–110]      | 0.001  |
| PMA at VP shunt, weeks                   | 44.7 [41.4–52.6] | 35.5 [32.0–41.0] | 0.002  |
| Interval b/w first op and VP shunt, days | 79 [40–111]      | 22 [10–34]       | <0.001 |

### Baseline and Surgical Characteristics according to Fibrinolysis Tx


| Values                                   | Fibrinolysis (-)<br>N=63 | Fibrinolysis (+)<br>N=45 | p     |
|--|--------------------------|--------------------------|-------|
| Gestational age, week                    | 27.6 [26.3-30.1]         | 27.7 [25.5-30.0]         | 0.995 |
| Weight at birth, g                       | 1040 [860-1520]          | 1060 [775-1430]          | 0.691 |
| Male, n (%)                              | 31 (49.2)                | 18 (40)                  | 0.383 |
| Inborn, n(%)                             | 9 (14.2)                 | 7 (15.6)                 | 0.828 |
| Postnatal days at diagnosis of IVH≥ GIII | 6 [3-14]                 | 7 [3-11]                 | 0.900 |
| Postnatal days at first operation        | 62 [39-99]               | 55 [20-80]               | 0.044 |
| Frequency of operation                   | 4 [3-6]                  | 6 [4.5-7]                | 0.019 |
| Postnatal days at VP shunt, days         | 143 [109-179]            | 148 [123-184]            | 0.280 |
| PMA at VP shunt, weeks                   | 47.6 [44.8-52.6]         | 50.3 [46.0-53.9]         | 0.078 |
| Interval b/w first op and VP shunt, days | 66 [43-96]               | 96 [69-130]              | 0.002 |



### Prevalence of VP shunt-related complications within 1 year

All VP shunt-received patients

Comparison of shunt-related complications within 1 year between groups



| Complication type | Group A       | Group B    | p-value | OR (95% CI)       |
|-------------------|---------------|------------|---------|-------------------|
| Shunt Infection   | 19/105 (18.1) | 4/7 (57.1) | 0.032   | 6.04 (1.25–29.22) |
| Shunt revision    | 16/102 (15.7) | 5/8 (62.5) | 0.006   | 8.96 (1.94–41.27) |

#### Group A patients, fibrinolysis (+) vs. (-)

| Complication type | Fibrinolysis (-) | Fibrinolysis (+) | p-value | OR (95% CI)      |
|-------------------|------------------|------------------|---------|------------------|
| Shunt Infection   | 8/60 (13.3)      | 11/45 (24.4)     | 0.200   | 2.10 (0.77–5.76) |
| Shunt malfunction | 12/57 (21.1)     | 4/45 (8.9)       | 0.108   | 0.37 (0.11–1.23) |

## Discussion

- Active and early neuroendoscopic intervention improved PHH control and reduced infection rates during the temporary management period, allowing delayed but safer shunt insertion with improved physical growth.
- By allowing shunt surgery after further maturation, this approach may help reduce shunt-related complications, leading to better overall outcomes.
- Further studies with larger, severity-matched cohorts and integrated brain MRI analysis are needed to better elucidate its long-term neurodevelopmental impact.

## References

Luyt K, Jary SL, Lea CL, Young GJ, Odd DE, Miller HE, Kmita G, Williams C, Blair PS, Hollingworth W, Morgan M, Smith-Collins AP, Walker-Cox S, Aquilina K, Pople I, Whitelaw AG. Drainage, irrigation and fibrinolytic therapy (DRIFT) for posthaemorrhagic ventricular dilatation: 10-year follow-up of a randomised controlled trial. *Arch Dis Child Fetal Neonatal Ed.* 2020;105(5):466–473. doi:10.1136/archdischild-2019-318231.

Tirado-Caballero J, Rivero-Garvia M, Arteaga-Romero F, Herreria-Franco J, Lozano-Gonzalez Á, Marquez-Rivas J. Neuroendoscopic lavage versus traditional surgical methods for the management of posthemorrhagic hydrocephalus in preterm infants: safety, effectivity, and lessons learned. *J Neurosurg Pediatr.* 2020;26(3):237–246. doi:10.3171/2020.2.PEDS2037.

Dvalishvili A, Khinikadze M, Gegia G, Khutsishvili L. Neuroendoscopic lavage versus traditional surgical methods for the early management of posthemorrhagic hydrocephalus in neonates. *Childs Nerv Syst.* 2022;38(10):1897–1902. doi:10.1007/s00381-022-05606-4.

Park YS, Motoyama Y, Kotani Y, Nakase H, Kim TK, Yokota H, Sugimoto T, Nakagawa I. Efficacy and safety of intraventricular fibrinolytic therapy for post-intraventricular hemorrhagic hydrocephalus in extremely low birth weight infants: a preliminary clinical study. *Childs Nerv Syst.* 2020;36(10):2471–2479. doi:10.1007/s00381-020-04791-7.

Park EK, Kim JY, Kim DS, Shim KW. Temporary surgical management of intraventricular hemorrhage in premature infants. *J Korean Neurosurg Soc.* 2023 Mar 30. [Epub ahead of print] doi:10.3340/jkns.2022.0265.

Honeyman SI, Boukas A, Jayamohan J, Magdum S. Neuroendoscopic lavage for the management of neonatal post-haemorrhagic hydrocephalus: a retrospective series. *Childs Nerv Syst.* 2022;38(1):115–121. doi:10.1007/s00381-021-05373-8.